Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Intangibles (2017 - 2023)

Aclaris Therapeutics (ACRS) has 7 years of Intangibles data on record, last reported at $7.0 million in Q1 2023.

  • For Q1 2023, Intangibles changed N/A year-over-year to $7.0 million; the TTM value through Mar 2023 reached $7.0 million, changed N/A, while the annual FY2022 figure was $7.4 million, 4.71% up from the prior year.
  • Intangibles reached $7.0 million in Q1 2023 per ACRS's latest filing, down from $7.4 million in the prior quarter.
  • Across five years, Intangibles topped out at $7.4 million in Q4 2020 and bottomed at $751000.0 in Q3 2019.
  • Average Intangibles over 5 years is $6.3 million, with a median of $7.1 million recorded in 2021.
  • Peak YoY movement for Intangibles: tumbled 89.7% in 2019, then rose 4.71% in 2022.
  • A 5-year view of Intangibles shows it stood at $7.2 million in 2019, then rose by 2.51% to $7.4 million in 2020, then decreased by 4.5% to $7.0 million in 2021, then rose by 4.71% to $7.4 million in 2022, then fell by 5.77% to $7.0 million in 2023.
  • Per Business Quant database, its latest 3 readings for Intangibles were $7.0 million in Q1 2023, $7.4 million in Q4 2022, and $7.0 million in Q4 2021.